• Chemistry Analysis
  • Separation Center
  • Center of Natural Product
  • Impurity Isolation and Identification
  • Physicochemical Characterization & Others
  • Pharmaceutical Analysis
  • ASMS Screening
  • Biology
  • In vitro Biology
  • Enzymes/Biochemical Assays
  • Ion Channel
  • Cellular Assays
  • GPCR, Transporter and NHR
  • Radioactive Assays
  • Cancer Cell Panel & In Vitro Oncology Assays
  • In Vitro Assays for Diabetes and Other Metabolic Diseases
  • High Throughput Screening
  • High Content Platform
  • Protein Expression and Purification
  • In vivo Pharmacology & PK/PD
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Fibrosis: Lung, Liver, Kidney
  • Central Nervous System & Pain
  • Respiratory: Asthma & COPD
  • IBS/IBD Animal Models
  • Large Animal Disease Models
  • Infectious Disease
  • Antiviral Services
  • Virology Assays Supporting Human Clinical Trials
  • Antibacterial In Vitro Screening and Pharmacology Services
  • HBV Platform
  • Safety and Early Toxicity
  • In Vitro Safety Profiling for Medchem Support
  • In Vitro Tox Assays for Medchem Support
  • Early Stage Safety Assessment
  • Oncology & Immunology
  • CRISPR/Cas9 Gene Editing
  • In Vitro & In Vivo Library Screening
  • In Vivo CRISPR Animal Models and Services
  • Gene Therapy
  • Tumor Models
  • Cell Line-Derived Xenograft (CDX) Tumor Models
  • Patient-Derived Xenograft (PDX) Tumor Models
  • Syngeneic Tumor Models
  • Human Immune Checkpoint Gene KI Mouse Models
  • hPBMC/HSC Humanized Models
  • Immuno-oncology
  • Translational Oncology
  • Biomarker
  • Discovery Biomarker
  • Clinical Biomarker
  • Autoimmune and Inflammatory Animal Models
  • OncoWuXi Database
  • Structure Based Drug Discovery
  • Protein Production
  • X-ray Crystallography
  • CryoEM
  • Biophysical Assays and Screening
  • FBDD - Fragment Screening
  • Biopharmaceutical Assays
  • Crelux
  • HD Biosciences
  • About Us
  • About WuXi RSD
  • RSD Leadership
  • About WuXi AppTec
  • News & Events
  • News
  • Upcoming Events
  • Resource Library
  • Newsletters
  • Latest Sciences
  • Literature Download
  • Contact
  • CN
    HBV Platform

    Overview

    Chronic hepatitis B (CHB) is a severe public health burden and an unmet medical need. Current standard therapies, interferon-α and nucleot(s)ides, cannot eliminate HBV. Recently, various novel targets and approaches are being explored towards the cure of CHB.  The Biology HBV team in Research Service Division (RSD) at WuXi AppTec, led by a group of experienced scientists with in-depth knowledge in anti-HBV drug discovery, has established and been providing an open access and full-range integrated HBV platform to our clients, including biochemical and cell-based assays, ex vivo PHH systems, animal models and clinical virology assays. The WuXi HBV team is your ideal partner for discovery and development of novel anti-HBV agents.

     

    Services

    A broad assay platform for the discovery of agents for the treatment of chronic HBV infection. Services for assay establishment and validation, compound screening and characterization, and support of preclinical studies and clinical trials.

     

    In Vitro Assays

  • (1) HBV stable cell lines : HepG2.2.15, DE19 and DES19
  •     -HBV DNA, cccDNA (qPCR, dot blot, Southern blot)
  •     -HBV antigens (ELISA, IHC, Western blot)
  •     -HBV RNAs (Northern blot, RT-qPCR)
  •     -Encapsidated RNA and DNA
  •     -Capsid content
  • (2) HBV DNA constructs with transient transfection assay
  • (3) Clinical isolates/genotype A to J (~5 strains for each genotype)
  • (4) Nucleot(s)ide and capsid inhibitor resistant mutants
  • (5) Phenotyping with shuttle vectors and mutant constructs
  •     -Fitness
  •     -Drug sensitivity
  • (6) HepG2-NTCP cell/HBV infectious system
  • (7) Reporter cell lines (hTLR, THP1-Blue ISG, TNF-induced NF-κB-luciferase, and IFN-α/β induction SEAP)
  • (8) Production of HBV from HBV stable cell lines
  • (9) Recombinant core protein expression and purification, and capsid quenching assay
  • (10) MOA studies
  •  

    Ex Vivo Primary Human Hepatocytes (PHH)

  • Fresh isolated and cryopreserved PHH
  • In vitro HBV infection
  • In vivo HBV infection 
  •  

    PK/PD Study and HBV Animal Model Related Immunology Assays

  • Cytokines by ELISA, Luminex and MSD
  • IFN and ISG mRNA by ELISA and RT-qPCR
  • Immune markers by IHC, IF and Western blot
  • Splenocytes, lymphocytes from organs and PBMC by FACS, ICS and ELISPOT 
  •  

    Animal Models

  • Hydrodynamic injection (HDI) mouse model
  • AAV/HBV mouse model
  • Humanized FRG mouse model
  • WHV/woodchuck model
  •  

    Activity of ETV in AAV/HBV Mice

     

     

    Clinical Virology (CAP lab)

  • Viral load (Cobas)
  • Sequencing: Pol, core, full-length sequencing, sanger (clone and population), deep sequencing
  • Genotyping by INNO-LiPA
  • Phenotyping
  • HBV emerging markers: serum HBV RNA, HBcrAg
  •  

    Business Contact 

  • North America: Declan Ryan,  declan.ryan@wuxiapptec.com
  • Europe and Israel: Dave Madge,  dave_madge@wuxiapptec.com
  • China: Marcher Xu,  xu_longji@wuxiapptec.com
  • Japan: Yan Zhu,  yan_zhu@wuxiapptec.com
  • Korea: Suk Young Cho,  sycho@wuxiapptec.com